Payment overview · 2025
General Payments
$1,238.85
36 reported records · 17 companies
Healthcare provider profile · identity verified
Mark Gerard Byrne, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Interventional Cardiology · WATSONVILLE, CA · NPI 1962411272
Verified facts
What the public records show
CMS Open Payments records show Mark Gerard Byrne, M.D. received $1,238.85 in general payments during 2025 across 36 reported records.
HEARTFLOW, INC. accounted for 27.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Kerendia, Ozempic, Rexulti, Rybelsus, Trelegy Ellipta, Wegovy.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 114 claims for Farxiga by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Trelegy Ellipta by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Rybelsus by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Wegovy as an associated drug or biological on 183056 records involving 75256 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Wegovy by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| HEARTFLOW, INC. | Unresolved — no canonical attribution shown | $338.30 | 27.3% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $275.83 | 22.3% | 11 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $172.23 | 13.9% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $60.30 | 4.9% | 3 | 2025 |
| Itamar Medical Inc | Unresolved — no canonical attribution shown | $56.66 | 4.6% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $52.19 | 4.2% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $45.42 | 3.7% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $44.58 | 3.6% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $31.83 | 2.6% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $31.37 | 2.5% | 1 | 2025 |
| DePuy Synthes Sales Inc. | Unresolved — no canonical attribution shown | $23.36 | 1.9% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $21.54 | 1.7% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $20.40 | 1.6% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $18.67 | 1.5% | 1 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $16.72 | 1.4% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.96 | 1.3% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.49 | 1.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,238.85 | 36 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FFRct Normalized: ffrct |
Device | HEARTFLOW, INC. | $338.30 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $172.23 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $151.84 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $123.99 | 6 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $64.09 | 3 | 2025 |
Source payment records
|
|||||
| WatchPATONE Normalized: watchpatone |
Device | Itamar Medical Inc | $56.66 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $52.19 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $50.83 | 2 | 2025 |
Source payment records
|
|||||
| LOKELMA Normalized: lokelma |
Drug | AstraZeneca Pharmaceuticals LP | $42.66 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $31.83 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $31.83 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $31.37 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $30.44 | 1 | 2025 |
Source payment records
|
|||||
| ORTHOVISC Normalized: orthovisc |
Device | DePuy Synthes Sales Inc. | $23.36 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $21.54 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $20.40 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $17.64 | 1 | 2025 |
Source payment records
|
|||||
| Vest Therapy Und Normalized: vest therapy und |
Device | Philips North America LLC | $16.72 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $15.96 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $14.14 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $13.49 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 62 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 114 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 68 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 46 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 70 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 31 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 56 | exact normalized | Medicare Part D |
| Wegovy wegovy |
2025 | Wegovy | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
114 | 34 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
46 | 15 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
68 | 25 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
62 | 18 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
56 | 16 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
70 | 16 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
31 | 14 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Wegovy open payments reported associated product |
CMS Open Payments — General Payments 183056 supporting records · 75256 recipient NPIs · example record 1188130070 |
Wegovy · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Carvedilol | Carvedilol | 541 | 138 |
| Losartan Potassium | Losartan Potassium | 512 | 156 |
| Atorvastatin Calcium | Atorvastatin Calcium | 477 | 144 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 358 | 106 |
| Irbesartan | Irbesartan | 324 | 85 |
| Montelukast Sodium | Montelukast Sodium | 275 | 82 |
| Metformin Hcl | Metformin Hcl | 254 | 76 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 248 | 38 |
| Gabapentin | Gabapentin | 230 | 69 |
| Omeprazole | Omeprazole | 226 | 69 |
| Levothyroxine Sodium | Levothyroxine Sodium | 212 | 57 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 190 | 50 |
| Amlodipine Besylate | Amlodipine Besylate | 186 | 54 |
| Alprazolam | Alprazolam | 140 | 29 |
| Mounjaro | Tirzepatide | 139 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 135 | 35 |
| Tamsulosin Hcl | Tamsulosin Hcl | 118 | 33 |
| Duloxetine Hcl | Duloxetine Hcl | 116 | 32 |
| Farxiga | Dapagliflozin Propanediol | 114 | 34 |
| Xarelto | Rivaroxaban | 109 | 24 |
| Furosemide | Furosemide | 94 | 27 |
| Alendronate Sodium | Alendronate Sodium | 93 | 28 |
| Diclofenac Sodium | Diclofenac Sodium | 92 | 38 |
| Ezetimibe | Ezetimibe | 81 | 28 |
| Spironolactone | Spironolactone | 77 | 23 |
| Lorazepam | Lorazepam | 73 | 17 |
| Pantoprazole Sodium | Pantoprazole Sodium | 73 | 19 |
| Chlorthalidone | Chlorthalidone | 72 | 21 |
| Ozempic | Semaglutide | 70 | 16 |
| Jardiance | Empagliflozin | 68 | 25 |
| Nitroglycerin | Nitroglycerin | 67 | 47 |
| Zolpidem Tartrate | Zolpidem Tartrate | 66 | 12 |
| Lisinopril | Lisinopril | 63 | 22 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 62 | 47 |
| Eliquis | Apixaban | 62 | 18 |
| Ketoconazole | Ketoconazole | 56 | 29 |
| Metoprolol Tartrate | Metoprolol Tartrate | 56 | 18 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 56 | 16 |
| Tramadol Hcl | Tramadol Hcl | 52 | 19 |
| Allopurinol | Allopurinol | 50 | 17 |
| Breo Ellipta | Fluticasone/Vilanterol | 49 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 47 | 13 |
| Kerendia | Finerenone | 46 | 15 |
| Quetiapine Fumarate | Quetiapine Fumarate | 46 | 12 |
| Hydrochlorothiazide | Hydrochlorothiazide | 45 | 14 |
| Amiodarone Hcl | Amiodarone Hcl | 44 | 11 |
| Lidocaine | Lidocaine | 44 | 23 |
| Metoclopramide Hcl | Metoclopramide Hcl | 43 | 13 |
| Trulicity | Dulaglutide | 43 | 13 |
| Memantine Hcl | Memantine Hcl | 42 | suppressed |
| Ibuprofen | Ibuprofen | 41 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 39 | 15 |
| Potassium Chloride | Potassium Chloride | 38 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 37 | 11 |
| Clonidine Hcl | Clonidine Hcl | 36 | 15 |
| Torsemide | Torsemide | 35 | 11 |
| Trazodone Hcl | Trazodone Hcl | 33 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 32 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 31 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 31 | suppressed |
| Rybelsus | Semaglutide | 31 | 14 |
| Simvastatin | Simvastatin | 31 | suppressed |
| Azithromycin | Azithromycin | 30 | 26 |
| Myrbetriq | Mirabegron | 30 | 14 |
| Colchicine | Colchicine | 29 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 28 | suppressed |
| Clonazepam | Clonazepam | 28 | 12 |
| Glipizide | Glipizide | 28 | suppressed |
| Olanzapine | Olanzapine | 28 | suppressed |
| Entresto | Sacubitril/Valsartan | 27 | suppressed |
| Pregabalin | Pregabalin | 27 | suppressed |
| Januvia | Sitagliptin Phosphate | 26 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 25 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 25 | 15 |
| Amitriptyline Hcl | Amitriptyline Hcl | 24 | suppressed |
| Celecoxib | Celecoxib | 22 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 21 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 20 | suppressed |
| Diazepam | Diazepam | 20 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 20 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 20 | suppressed |
| Repaglinide | Repaglinide | 19 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 19 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 18 | suppressed |
| Lansoprazole | Lansoprazole | 18 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 18 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 18 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 18 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 17 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 17 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 16 | 14 |
| Finasteride | Finasteride | 16 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 16 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 16 | suppressed |
| Meloxicam | Meloxicam | 16 | suppressed |
| Nystatin | Nystatin | 16 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 16 | suppressed |
| Digoxin | Digoxin | 15 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 15 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 15 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 15 | suppressed |
| Sucralfate | Sucralfate | 15 | suppressed |
| Humalog | Insulin Lispro | 14 | suppressed |
| Repatha Sureclick | Evolocumab | 14 | suppressed |
| Telmisartan | Telmisartan | 14 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 14 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 14 | suppressed |
| Famotidine | Famotidine | 13 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Valsartan | Valsartan | 13 | suppressed |
| Xtampza Er | Oxycodone Myristate | 13 | suppressed |
| Estradiol | Estradiol | 12 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 12 | suppressed |
| Repatha Syringe | Evolocumab | 12 | suppressed |
| Rexulti | Brexpiprazole | 12 | suppressed |
| Wegovy | Semaglutide | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Aripiprazole | Aripiprazole | 11 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 11 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 11 | suppressed |
| Serevent Diskus | Salmeterol Xinafoate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,238.85 · 36 records | HEARTFLOW, INC. | AREXVY, AUSTEDO XR, ELIQUIS, EVENITY, FARXIGA, FFRct, JARDIANCE, Kerendia, LOKELMA, NUZYRA, ORTHOVISC, Ozempic, PROLIA, REXULTI, Rybelsus, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, Vest Therapy Und, WatchPATONE, Wegovy, YUPELRI | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error